Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,705 total articles
TotalEnergies is trading at $87.26 with a market cap near $198B, a P/E of 10.6 and a 4.4% dividend yield. The company is benefiting from elevated commodity realizations and operational progress on projects like GranMorgu, while integrating AI and digital partners to shave costs. We favor a mid-term long (45 trading days) entry designed to capture d…
Nvidia's 08/26/2026 quarter blew past expectations: $96.2B revenue (106% YoY), $29.2B adjusted net income, and management guiding to $108B for the next quarter. The market has briefly priced in deceleration despite record profits; that disconnect creates an asymmetric risk/reward for a disciplined long with a $223 entry, $200 stop and $300 target o…
Cogent Biosciences (COGT) has lined up three regulatory filings for bezuclastinib across Non-Advanced Systemic Mastocytosis (NonAdvSM), Advanced Systemic Mastocytosis (AdvSM) and GIST. FDA acceptance and robust SUMMIT data support a tactical long into the late-2026 decision window. Entry at $37.00, stop at $30.00, target $60.00, long term (180 trad…
Joby has industry-leading progress on FAA certification and deep pockets from partners, yet the stock remains priced for perfection (price-to-sales ~61x) and management's recent capital actions have increased dilution risk. Trade the squeeze between regulatory headlines and financing overhang: short with a tight stop and a mid-term horizon to captu…
Quanta Services (PWR) has been hit by a rapid derating from its 2026 highs. The selloff creates a favorable risk-reward: the company sports a near-record backlog, healthy free cash flow and shareholder-friendly actions, while valuation and sentiment have pulled back enough to justify a tactical long. This trade idea lays out an entry at $620.00, a …
Synopsys is the core EDA and IP provider quietly baked into the chip design flows that power next-generation AI chips. With a $78.5B market cap, $2.75B in free cash flow and partnership momentum around agentic engineering toolkits, the stock looks like a tactical buy on strength in design automation demand. This trade plan buys the stock near curre…
GSK ($51.44) combines a resilient commercial franchise, meaningful vaccine exposure and a mid-teens P/E with a 3.4% yield. Technicals are neutral-to-bullish and the company sits squarely in expanding vaccine markets (influenza, HPV). I recommend a long trade sized for a diversified portfolio: entry $51.40, primary target $62.00, stop loss $48.00, h…
Siemens Energy has pushed through a painful restructuring cycle. With improved execution across Gas, Grid, and Siemens Gamesa, the stock looks primed for a tactical long. This trade targets a recovery driven by backlog conversion, better margin trajectory and falling working capital pressure.
Zymeworks is shifting its identity from a development-stage biotech to a hybrid commercial/royalty-driven platform. With licensed assets in the mix, a $929M acquisition of Theravance (bringing YUPELRI® with $266.6M in 2025 U.S. sales), fresh commercial upside and a deeper R&D bench, the company has optionality that could justify a higher multiple. …
Okta's fundamentals and guidance from the May quarter keep the buy case intact: 11% revenue growth in Q1 to $765M, $271M of FCF in the quarter and a FY27 revenue guide near $3.2B. However, the stock now trades at a premium (EV/sales ~7.7, trailing P/E ~95) and recent outperformance narrows the margin for execution mistakes. This trade proposes a di…
AT&T trades at $25.89 with a 4.5% yield, a single-digit P/E and an EV/EBITDA of ~6.5. The balance sheet still carries leverage, but free cash flow of ~$13.3B and a 36-45% payout framework make the dividend resilient. This trade targets a reversion toward the 52-week high and a modest re-rating as subscriber stability, cash flow and buybacks normali…
Bloom Energy is trading like a growth juggernaut after a string of blowout quarters and a $20 billion backlog. Fundamentals justify the story, but the valuation is demanding. This is a structured swing trade: respect the premium, limit position size, and use a tight stop to capture a potential re-rating while protecting against profit-taking.
Waste Management is a high-quality compounder: strong ROE (28.7%), predictable free cash flow ($3.57B), and essential services that keep revenue resilient in downturns. At $221, the stock is priced richly (P/E ~31, P/B ~8.9, EV/EBITDA ~14.3). This trade idea recommends waiting for a pullback to $205 to initiate a position, using a $195 stop, and ta…
Celestica's role as an assembler of complex AI server racks and its strong Q1 print and raised guidance position it to benefit disproportionately if the so-called 'Jalapeño' AI chip ramps hit hyperscalers. Valuation is elevated but not prohibitive given $19B revenue guidance and robust profitability metrics. We upgrade to Buy and outline a mid-term…
Urban Outfitters is delivering above-consensus results, expanding margins and converting subscription strength into healthier cash flow. The shares trade at a reasonable multiple against steady fundamentals and improving operating metrics. We upgrade to a buy and propose a clear swing trade: entry $83.00, target $95.00, stop $74.00 over a 45 tradin…
Super Micro (SMCI) sits at the intersection of surging AI-server demand and capital strain. Order momentum, improving gross margins and strong quarterly earnings justify a buy, but a $6.85B trailing free-cash-flow hole, ongoing equity raises, and regulatory/governance overhangs make position sizing and stops essential.
Disney is trading at a reasonable multiple today despite strong cash flow and a resurgent experiences business. If theatrical multiplex attendance and studio monetization recover — and streaming margins stabilize — Disney's current $189B market cap and $230B enterprise value look conservative. This trade idea lays out an actionable buy with entry, …
Ichor is benefitting from accelerating semiconductor capex: revenue run-rates have moved above $240m per quarter and management expects sequential growth through 2026. The stock has momentum but still trades at reasonable enterprise-value-to-sales near 2.0. I recommend a tactical long swing with strict risk control while watching margins and cash f…
ArcelorMittal (MT) has been reshaping its business into regionally run hubs with greater vertical integration and targeted sustainable capex. That structural shift should compress cyclicality, improve margins over time and support multiple expansion from trough levels. We like a tactical long at current prices with a clear stop and a mid-to-long ho…
Vertiv sits squarely in the crosshairs of the AI data center power and cooling shortage. Strong free cash flow, healthy margins and an expanding addressable market justify a bullish, mid-term swing trade, but lofty multiples and execution risk demand a tight stop and clear exit plan.
LPL Financial (LPLA) remains our preferred way to play advisor-led wealth management exposure. Continued advisor onboarding, pockets of AUM wins (including a $2.4B team), a healthy ROE, and rising rates that fatten cash yields on client balances underpin a bullish thesis. Valuation is not cheap at ~28x earnings, but operational leverage and improvi…
Alphabet is funding a massive AI buildout that has turned shareholders into backers. If Alphabet successfully commercializes its Tensor Processing Units (TPUs) and related hardware/services, the company can recover capital intensity with much higher returns on invested capital. We lay out a trade: enter at $342.06, stop at $320.00, target $420.00 o…
Zoom's equity stake in Anthropic plus deep product integration with Claude creates a direct, near-term catalyst. Fundamentals and FCF generation make a well-contained risk-reward for a swing trade. Upgrade to Buy with a clear plan: entry $95.00, stop $85.00, target $125.00 over the next 45 trading days.
EyePoint (EYPT) sold off after a disappointing readout in Lugano. The market is punishing clinical disappointment, pushing the shares toward a 52-week low, yet the company still carries roughly $223M in runway, manageable enterprise value, and ongoing Phase 3 catalysts. For traders willing to accept biotech binary risk, a controlled swing long offe…
Adyen remains a high-quality payments franchise with durable unit economics and a substantial cash balance. On a pure free-cash-flow basis the stock looks fairly valued today, but the company's net cash and recurring merchant relationships create a lower-risk asymmetric trade if you buy a controlled pullback. This trade idea outlines an actionable …
